MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
PGEN stock logo

PGEN

Precigen, Inc.

$3.71
0.14
 (3.92%)
Exchange:  NASDAQ
Market Cap:  1.115B
Shares Outstanding:  167.066M
Delayed data
Calculate PGEN Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Biotechnology
   
CEO:  Helen Sabzevari
Full Time Employees:  143
Address: 
20374 Seneca Meadows Parkway
Germantown
MD
20876
US
Website:  https://www.precigen.com
Precigen, Inc. is an American company dedicated to the discovery and development of cutting-edge gene and cellular therapies. The company also offers disease-modifying treatments, genetically engineered swine for regenerative medicine, and advanced reproductive and embryo transfer technologies. Its extensive portfolio of proprietary platforms includes UltraVector, which leverages advanced DNA construction and computational modeling to engineer complex gene expression programs; mbIL15, a gene designed to enhance immune cell function; the non-viral Sleeping Beauty transposon/transposase system for genetic modification; and AttSite recombinases, tools for precise DNA recombination. Furthermore, Precigen utilizes its AdenoVerse platform, a library of engineered adenovectors for gene delivery and immunotherapy applications, alongside L. lactis, a food-grade bacterium. The company also provides RheoSwitch, an inducible gene switch system offering quantitative, dose-proportionate control over target protein expression’s timing and amount; kill switches, designed to selectively eliminate cell therapies within the body; tissue-specific promoters for targeted gene expression; the UltraCAR-T platform for cancer treatment; and the ActoBiotics platform, which employs genetically modified bacteria to deliver proteins and peptides directly to mucosal sites. Precigen maintains strategic collaboration and license agreements with Alaunos Therapeutics, Inc., Ares Trading S.A., Oragenics, Inc., Castle Creek Biosciences, Inc., and Intrexon Energy Partners I and II, LLC. Established in 1998, Precigen, Inc., previously known as Intrexon Corporation, adopted its current name in January 2020 and is headquartered in Germantown, Maryland.

Click to read more…

Revenue Segmentation

MARKETSnap
MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/05/13 — Q1 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue6,2253,9259,684
Gross Profit106-3423,588
EBITDA-89,226-123,496-103,401
Operating Income-99,758-135,029-106,600
Net Income-95,904-126,235-250,642

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets151,043145,266155,505
Total Liabilities32,545106,753134,594
Total Stockholders Equity118,49866,730.99920,911
Total Debt7,0975,50298,290
Cash and Cash Equivalents7,57829,51730,234

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-66,930-68,173-87,831
Capital Expenditure-1,536-8,5840
Free Cash Flow-68,466-76,757-87,831
Net Income-95,904-126,235-250,642
Net Change in Cash-40,74821,6690

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)718,550.225Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)871,103.446Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)785,679Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)-871,103.446Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)-718,550.225Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)-785,679Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)390,044.068Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)500,799.202Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)438,779.008Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)3,741,997.959Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)4,536,450.207Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)4,091,584.850Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)1.440Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)1.640Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)1.280Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)1Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)1Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
6.225M  ?P/S
 (TTM)
: 
34.04
?Net Income
 (TTM)
: 
-95904000  ?P/E
 (TTM)
: 
-5.48
?Enterprise Value
 (TTM)
: 
1.166B  ?EV/FCF
 (TTM)
: 
-9.92
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0
?ROE
 (TTM)
: 
-17.69  ?ROIC
 (TTM)
: 
-0.79
?Net Debt
 (TTM)
: 
-22882000  ?Debt/Equity
 (TTM)
: 
4.86
?P/B
 (TTM)
: 
55.37  ?Current Ratio
 (TTM)
: 
4.82

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
N/AFull AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about PGEN valuation

Is Precigen, Inc. (PGEN) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Precigen, Inc. (PGEN) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is PGEN a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether PGEN trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is PGEN’s P/E ratio?

You can see PGEN’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for PGEN?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is PGEN a good long-term investment?

Whether PGEN fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

PGEN

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

3.92
MARKETSnap

Trading Metrics:

Open: 3.66   Previous Close: 3.57
Day Low: 3.56   Day High: 3.75
Year Low: 1.38   Year High: 5.47
Price Avg 50: 4.08   Price Avg 200: 4.02
Volume: 3.474M   Average Volume: 4.346M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Precigen, Inc. (PGEN) is a Great Momentum Stock: Should You Buy?
01-06-2026 13:02
Precigen, Inc. (PGEN) is a Great Momentum Stock: Should You Buy?
Precigen: Why I Am More Cautious After The Q1 Beat (Downgrade)
21-05-2026 16:52
Precigen: Why I Am More Cautious After The Q1 Beat (Downgrade)
Precigen: Full Commercial Validation And Room To Run
14-05-2026 09:58
Precigen: Full Commercial Validation And Room To Run
Precigen Q1 Earnings Call Highlights
14-05-2026 00:14
Precigen Q1 Earnings Call Highlights
Precigen, Inc. (PGEN) Q1 2026 Earnings Call Transcript
13-05-2026 22:40
Precigen, Inc. (PGEN) Q1 2026 Earnings Call Transcript
Precigen, Inc. (PGEN) Discusses Launch and Differentiation of PAPZIMEOS Immunotherapy for Adult RRP Transcript
01-04-2026 01:32
Precigen, Inc. (PGEN) Discusses Launch and Differentiation of PAPZIMEOS Immunotherapy for Adult RRP Transcript

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read